AEON BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.77 USD | +11.32% |
|
-50.42% | -75.42% |
| May. 03 | US Equity Markets Close Higher Friday Following Weak Jobs Report | MT |
| May. 03 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 61.66M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.45% | ||
| 1 week | -58.70% | ||
| Current month | -58.70% | ||
| 1 month | -81.07% | ||
| 3 months | -82.83% | ||
| 6 months | -65.58% | ||
| Current year | -77.92% |
1 week
1.38
3.57
1 month
1.388.60
Current year
1.3817.17
1 year
1.3817.17
3 years
1.3817.17
5 years
1.3817.17
10 years
1.3817.17
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 1.77 | +11.32% | 119 997 |
| 24-05-07 | 1.59 | -2.45% | 141,854 |
| 24-05-06 | 1.63 | -4.12% | 219,422 |
| 24-05-03 | 1.7 | -49.40% | 931,639 |
| 24-05-02 | 3.36 | -5.88% | 69,068 |
Delayed Quote Nyse, May 07, 2024 at 04:00 pm EDT
More quotes
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.59
USD
Average target price
18
USD
Spread / Average Target
+1,032.08%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -77.92% | 61.66M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +6.72% | 23.47B | |
| -13.89% | 21.9B | |
| -6.64% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- AEON Stock